| Primary |
| Product Used For Unknown Indication |
39.1% |
| Haematopoietic Stem Cell Mobilisation |
15.8% |
| Acute Myeloid Leukaemia |
14.3% |
| Drug Use For Unknown Indication |
4.4% |
| Prophylaxis |
3.7% |
| Myelodysplastic Syndrome |
2.9% |
| Multiple Myeloma |
2.6% |
| Bone Marrow Conditioning Regimen |
2.2% |
| Hypertension |
1.9% |
| Nausea |
1.9% |
| Pain |
1.8% |
| Acute Lymphocytic Leukaemia |
1.5% |
| Chronic Lymphocytic Leukaemia |
1.3% |
| Non-hodgkin's Lymphoma |
1.2% |
| Infection Prophylaxis |
1.0% |
| Premedication |
1.0% |
| Prophylaxis Of Nausea And Vomiting |
0.9% |
| Lymphoma |
0.9% |
| Acute Myeloid Leukaemia Recurrent |
0.8% |
| Antifungal Prophylaxis |
0.8% |
|
| Thrombocytopenia |
10.3% |
| Sepsis |
8.7% |
| Death |
6.5% |
| Febrile Neutropenia |
6.5% |
| Pyrexia |
6.5% |
| Nausea |
6.0% |
| Acute Myeloid Leukaemia |
4.9% |
| Vomiting |
4.9% |
| Deep Vein Thrombosis |
4.3% |
| White Blood Cell Count Decreased |
4.3% |
| Hypersensitivity |
3.8% |
| Infection |
3.8% |
| Interstitial Lung Disease |
3.8% |
| Metastases To Central Nervous System |
3.8% |
| Myocardial Infarction |
3.8% |
| Pancytopenia |
3.8% |
| Plasmacytoma |
3.8% |
| Therapeutic Response Decreased |
3.8% |
| Diarrhoea |
3.3% |
| Neutropenia |
3.3% |
|
| Secondary |
| Product Used For Unknown Indication |
32.9% |
| Acute Myeloid Leukaemia |
13.4% |
| Haematopoietic Stem Cell Mobilisation |
11.6% |
| Drug Use For Unknown Indication |
5.7% |
| Infection Prophylaxis |
5.0% |
| Prophylaxis |
4.9% |
| Premedication |
4.0% |
| Multiple Myeloma |
3.1% |
| Mineral Supplementation |
2.3% |
| Dry Eye |
2.2% |
| Bone Marrow Conditioning Regimen |
2.1% |
| Nausea |
2.1% |
| Myelodysplastic Syndrome |
1.8% |
| Diarrhoea |
1.6% |
| Hypertension |
1.3% |
| Prophylaxis Against Graft Versus Host Disease |
1.3% |
| Pain |
1.2% |
| Constipation |
1.2% |
| Gastrooesophageal Reflux Disease |
1.2% |
| Non-hodgkin's Lymphoma |
1.1% |
|
| Hyperbilirubinaemia |
17.1% |
| Urinary Tract Infection Enterococcal |
11.4% |
| Nausea |
7.0% |
| Therapeutic Response Decreased |
6.3% |
| Influenza |
5.1% |
| Pyrexia |
5.1% |
| Sepsis |
5.1% |
| Thrombocytopenia |
5.1% |
| Acute Myeloid Leukaemia |
4.4% |
| Neutropenia |
4.4% |
| Pneumothorax |
3.8% |
| Diarrhoea |
3.2% |
| Pancytopenia |
3.2% |
| Pneumonia |
3.2% |
| Septic Shock |
3.2% |
| Blood Stem Cell Harvest Failure |
2.5% |
| Cellulitis |
2.5% |
| Infection |
2.5% |
| Respiratory Failure |
2.5% |
| Upper Respiratory Tract Infection |
2.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
35.1% |
| Drug Use For Unknown Indication |
28.6% |
| Acute Myeloid Leukaemia |
7.1% |
| Diffuse Large B-cell Lymphoma |
6.0% |
| Haematopoietic Stem Cell Mobilisation |
5.4% |
| Bone Marrow Conditioning Regimen |
2.4% |
| Chronic Myeloid Leukaemia |
2.4% |
| Chemotherapy |
2.1% |
| Antifungal Treatment |
1.2% |
| Mineral Supplementation |
1.2% |
| Plasma Cell Myeloma |
1.2% |
| Premedication |
1.2% |
| Stem Cell Transplant |
1.2% |
| Stomatitis |
1.2% |
| Pain |
0.9% |
| Affective Disorder |
0.6% |
| Antiviral Treatment |
0.6% |
| Anxiety |
0.6% |
| Blood Pressure Abnormal |
0.6% |
| Central Venous Catheterisation |
0.6% |
|
| Venoocclusive Disease |
24.0% |
| Thrombocytopenia |
16.0% |
| Drug Ineffective |
8.0% |
| Acute Graft Versus Host Disease |
4.0% |
| Blood Immunoglobulin A Increased |
4.0% |
| Diarrhoea |
4.0% |
| Dizziness Postural |
4.0% |
| Escherichia Sepsis |
4.0% |
| Pallor |
4.0% |
| Plasma Cell Myeloma |
4.0% |
| Proctitis |
4.0% |
| Renal Failure |
4.0% |
| Renal Failure Acute |
4.0% |
| Stem Cell Transplant |
4.0% |
| Ventricular Tachycardia |
4.0% |
| Viral Haemorrhagic Cystitis |
4.0% |
|
